AIM To observe the clinical effect of amiodarone combined with esmolol in the treatment of ventricular arrhythmia in midrange ejection fraction heart failure (HFmrEF).
METHODS One hundred and ten cases of ventricular arrhythmia with HFmrEF were admitted to our hospital from January 2018 to January 2020 and they were randomly divided into amiodarone group and combined group, with 55 cases in each group. Amiodarone group was treated with oral amiodarone tablets on the base of corrective heart failure treatment, while combined group was treated with esmolol injection on the base of amiodarone group. The therapeutic effect, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV) and the incidence of adverse reactions were compared between the two groups before and after medication.
RESULTS After 48-hour treatment, SBP, DBP and heart rate of the two groups were lower than those before treatment (P<0.05), and those in combined group were lower than those in amiodarone group (P<0.05). After 4-week treatment, the significant effective rate and total effective rate in combined group were higher than those in amiodarone group (P<0.01). The levels of LVESV, LVEDV and LVEF in two groups after 4 weeks’ treatment were not significant different from those before treatment (P<0.05), and there was no statistical difference between the combined group and the amiodarone group. There was no significant difference in the incidence of adverse reactions between the two groups.
CONCLUSION Amiodarone combined with esmolol can effectively treat ventricular arrhythmia in HFmrEF patients with better safety,but there was no significant improvement in cardiac function.
DownLoad: